Table 3.
The influence of comorbidities on hematological parameters in patients with psoriasis versus atopic dermatitis.
| Parameter | PsO | AD | p | ||
|---|---|---|---|---|---|
| Without Comorbidities n = 19 |
With Comorbidities n = 21 |
Without Comorbidities n = 20 |
With Comorbidities n = 20 |
||
| PLT ×109/L | 265 (233–316) | 223 (158–244) a | 267 (237–315) | 234 (172–275) | 0.059 |
| PCT (L/L) | 0.0027 (0.0022–0.0029) |
0.0021 (0.0018–0.0025) a |
0.0026 (0.0024–0.0029) |
0.0023 (0.0018–0.0024) c |
0.044 |
| Lymphocytes (%) | 31.1 (26.5–36.4) | 37.4 (31.6–42.5) a | 29.9 (24.2–34.7) | 33.5 (27.8–40.8) | 0.030 |
| PLR | 112 (97–137) | 96 (60–107) a | 124 (98–165) | 96 (81–115) c | 0.008 |
| MPR | 0.033 (0.029–0.044) |
0.044 (0.036–0.062) a |
0.038 (0.029–0.040) |
0.040 (0.031–0.054) |
0.052 |
| RPR | 0.050 (0.040–0.058) |
0.057 (0.052–0.087) a |
0.050 (0.043–0.055) |
0.058 (0.044–0.088) c |
0.103 |
Data are presented as median (25–75 percentile), p-value: Kruskal–Wallis test; a p < 0.05 vs. PsO without comorbidities; c p < 0.05 vs. AD without comorbidities (Mann–Whitney U test).